SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-025197
Filing Date
2020-05-14
Accepted
2020-05-13 19:34:24
Documents
93
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bbio-10q_20200331.htm 10-Q 3981382
2 EX-31.1 bbio-ex311_6.htm EX-31.1 22094
3 EX-31.2 bbio-ex312_8.htm EX-31.2 22139
4 EX-32.1 bbio-ex321_10.htm EX-32.1 11918
5 EX-32.2 bbio-ex322_7.htm EX-32.2 11584
  Complete submission text file 0001564590-20-025197.txt   17299594

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT bbio-20200331.xml EX-101.INS 4880508
7 XBRL TAXONOMY EXTENSION SCHEMA bbio-20200331.xsd EX-101.SCH 96727
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE bbio-20200331_cal.xml EX-101.CAL 75853
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bbio-20200331_def.xml EX-101.DEF 414062
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20200331_lab.xml EX-101.LAB 687470
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20200331_pre.xml EX-101.PRE 614694
Mailing Address 421 KIPLING STREET PALO ALTO CA 94301
Business Address 421 KIPLING STREET PALO ALTO CA 94301 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38959 | Film No.: 20874920
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences